Assessment of the Safety, Tolerability, and Pharmacokinetic of GMA106
Status:
Not yet recruiting
Trial end date:
2023-04-03
Target enrollment:
Participant gender:
Summary
This will be a single centre, Phase 1, placebo-controlled, randomized, doubleblind,
sequential SAD study to assess the safety, tolerability, and PK of GMA106 in healthy
subjects.